YY
Therapeutic Areas
Pluri Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PLX‑PAD | Knee Osteoarthritis | Phase 3 |
Leadership Team at Pluri
LZ
Liat Zalts
Chief Financial Officer
LR
Lior Raviv
Chief Technology Officer
DM
Dr. Michal Sheleg, PhD
VP Clinical Development
NB
Nimrod Bar Zvi
Chief Commercial Officer
NG
Nofar Glaich‑Dabach
VP Human Resources
DA
Dr. Arthur Machlenkin, PhD
Chief Scientific Officer
OA
Orly Amir
Chief Quality Officer
OS
Ori Shalem
VP Operations and Manufacturing